In xenograft tumors derived from hepatocellular carcinoma patients with low LIF receptor subunit alpha expression and high expression of LCN, an LCN2‐neutralizing antibody enhances the ferroptosis‐inducing and anticancer effects (Yao et al., 2021). The gene discussed is LIFR; the disease is hepatocellular carcinoma.